Gain Therapeutics, INC 8-K filings

Gain Therapeutics reported positive progress in their Parkinson's disease drug trial and announced their financial results for the second quarter of 2024.

Gain Therapeutics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting its listing at risk.

Gain Therapeutics has completed dosing in the multiple ascending dose (MAD) portion of its Phase 1 study for GT-02287, a potential Parkinson's disease treatment, with no serious adverse events reported.

Gain Therapeutics has announced the departure of its CEO, Matthias Alder, and the appointment of Gene Mack as interim CEO, effective June 25, 2024.

Gain Therapeutics held its annual meeting on June 24, 2024, electing eight directors and ratifying Ernst & Young AG as its independent auditor.

Gain Therapeutics has announced the pricing of an underwritten public offering to raise approximately $11 million through the sale of common stock and pre-funded warrants.

Gain Therapeutics reported positive results from their Phase 1 clinical trial of GT-02287 and provided a financial update for the first quarter of 2024, showing reduced operating expenses and a smaller net loss per share.

Gain Therapeutics has appointed Gene Mack as its new Chief Financial Officer, effective April 8, 2024, bringing extensive experience in life sciences and finance.

Gain Therapeutics announced its financial results for the year ended December 31, 2023, and provided a corporate update, highlighting progress in its clinical programs and financial position.

Gain Therapeutics, Inc. reports the resignation of its Chief Financial Officer and the appointment of a new Principal Financial Officer, effective March 1, 2024.

Gain Therapeutics' CEO provided an update to shareholders, highlighting the company's transition to a clinical-stage biotech with its lead drug candidate, GT-02287, and its enhanced drug discovery platform, Magellan.